首页> 外文期刊>clinical drug investigation >ComparativeIn VitroActivity and Killing Effect of Trovafloxacin, DU-6859a, Levofloxacin and Sparfloxacin againstStaphylococcus aureusFocus on Methicillin-Resistant Isolates
【24h】

ComparativeIn VitroActivity and Killing Effect of Trovafloxacin, DU-6859a, Levofloxacin and Sparfloxacin againstStaphylococcus aureusFocus on Methicillin-Resistant Isolates

机译:ComparativeIn VitroActivity and Killing Effect of Trovafloxacin, DU-6859a, Levofloxacin and Sparfloxacin againstStaphylococcus aureusFocus on Methicillin-Resistant Isolates

获取原文
           

摘要

The predominance of quinolone resistance among methicillin-resistantStaphylococcus aureus(MRSA) isolates in the nosocomial environment led to thein vitrocomparison of trovafloxacin (CP-99,219) and DU-6859a (which are novel fluoroquinolone compounds) with levofloxacin (the L-geometric isomer of ofloxacin) and sparfloxacin against 152S. aureusisolates, 104 of which were MRSA. At 2 mgsol;L trovafloxacin and DU-6859a inhibited 92.3 and 77.9percnt; of MRSA isolates, respectively, possessing lower minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values than levofloxacin and sparfloxacin, which inhibited 38.5 and 36.5percnt; of isolates, respectively. In contrast, in the methicillin-susceptible population all tested fluoroquinolones had an equal intrinsic activity. Trovafloxacin possessed a superior killing effect compared with DU-6859a and sparfloxacin, whereas levofloxacin was the least bactericidal quinolone. Indeed, the effect of trovafloxacin was mainly expressed at a quinolone concentration of 2 times; MIC and after 24 hours of growth. However, in levofloxacin- and sparfloxacin-resistant MRSA isolates, DU-6859a had a superior killing effect compared with trovafloxacin. Trovafloxacin had a killing effect in only 20percnt; of DU-6859a-, levofloxacin- and sparfloxacin-resistant isolates. Our findings support trovafloxacin and DU-6859a as highly activein vitroantistaphylococcal agents, especially in MRSA, which merit further clinical investigation.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号